UroGen Pharma Ltd. — Operating Income by Fiscal Year
11 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/cc410032-12a3-45e8-b404-15693059d5b1/serie/operating-income
| Fiscal year | Operating Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $-124.9M | 2025-01-01 – 2025-12-31 | evidence 0001437749-26-006234 |
| FY 2024 | $-96.8M | 2024-01-01 – 2024-12-31 | evidence 0001437749-25-006842 |
| FY 2023 | $-65.5M | 2023-01-01 – 2023-12-31 | evidence 0001437749-24-007753 |
| FY 2022 | $-79.0M | 2022-01-01 – 2022-12-31 | evidence 0001437749-23-007710 |
| FY 2021 | $-92.3M | 2021-01-01 – 2021-12-31 | evidence 0001437749-22-006778 |
| FY 2020 | $-126.7M | 2020-01-01 – 2020-12-31 | evidence 0001564590-21-014016 |
| FY 2019 | $-109.5M | 2019-01-01 – 2019-12-31 | evidence 0001564590-20-007970 |
| FY 2018 | $-77.2M | 2018-01-01 – 2018-12-31 | evidence 0001564590-19-005323 |
| FY 2017 | $-19.9M | 2017-01-01 – 2017-12-31 | evidence 0001564590-18-005876 |
| FY 2016 | $798.0k | 2016-01-01 – 2016-12-31 | evidence 0001564590-18-005876 |
| FY 2015 | $-12.4M | 2015-01-01 – 2015-12-31 | evidence 0001564590-18-005876 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).